Literature DB >> 2878065

Comparative tolerability of labetalol versus propranolol, atenolol, pindolol, metoprolol, and nadolol.

J F Burris, J Goldstein, P G Zager, J M Sutton, M A Sirgo, J R Plachetka.   

Abstract

The side-effect profile of labetalol was assessed in 34 patients with mild to moderate essential hypertension who had previously experienced side effects during beta-blocker therapy. The most frequently reported beta-blocker side effects were fatigue, impotence, cold extremities, and depression. After discontinuing their previous beta-blocker for 4 weeks, labetalol was titrated (100-400 mg b.i.d.) to achieve blood pressure control. Twenty-seven of 34 patients did not have a recurrence of a beta-blocker related side effect while receiving labetalol. The most common new side effect with labetalol was dizziness (3 patients). As judged by the attending physician and the patient, labetalol was better tolerated than conventional beta-blocker therapy in 30 of 34 patients (88%). Twenty-four of 34 patients (71%) preferred labetalol over previous therapy. Labetalol controlled blood pressure in 30 of 34 patients (88%). At equal antihypertensive doses, some side effects common to beta-blockers are seen less frequently with labetalol.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2878065

Source DB:  PubMed          Journal:  J Clin Hypertens        ISSN: 0748-450X            Impact factor:   3.738


  3 in total

Review 1.  Novel Indications for Commonly Used Medications as Radiation Protectants in Spaceflight.

Authors:  Mark F McLaughlin; Dorit B Donoviel; Jeffrey A Jones
Journal:  Aerosp Med Hum Perform       Date:  2017-07-01       Impact factor: 1.053

2.  Sildenafil does not influence hepatic venous pressure gradient in patients with cirrhosis.

Authors:  Jens-Otto Clemmesen; Annamaria Giraldi; Peter Ott; Kim Dalhoff; Bent-Adel Hansen; Fin-Stolze Larsen
Journal:  World J Gastroenterol       Date:  2008-10-28       Impact factor: 5.742

3.  Acute renal failure associated with a labetalol overdose.

Authors:  A Korzets; P Danby; M E Edmunds; J Feehally; J Walls
Journal:  Postgrad Med J       Date:  1990-01       Impact factor: 2.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.